TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Korea Ginseng Corporation inaugurated its research and development (R&D) center in California. The leading South Korean ginseng producer said on Wednesday, March 15, that it has set up a facility in the United States to expand its presence in the American market while also boosting its sales overseas.
Korea Ginseng Corp. is the maker of the no. 1 ginseng brand in the world known as CheongKwanJang. The opening of its R&D center in the U.S. is a major step toward increasing its market share in the region. Moreover, the center was built so the company can continue developing Korean ginseng into a product that will suit the preference of Americans.
As per The Korea Herald, the ginseng products manufacturer said that with its new R&D center, it would conduct research to find ways of enhancing and broadening the use of its flagship red ginseng products currently being sold in the U.S.
The company especially wants to bolster its products' capability of improving customers' immunity and memory and reducing fatigue. Aside from product development, the center will also serve as a hub that will manage the manufacturing process and quality control of the health products that will be made there.
Korea Ginseng Corp. mentioned its R&D in California will further function as an office for its business ventures in neighboring foreign markets, including Central and South America. The facility will collect data about health drinks and food markets so the company can improve its products based on the information.
"Our US R&D Center will contribute to the construction of local production infrastructure while strengthening the development of customized ginseng products for local consumers," KGC's chief executive officer, Heo Chul Ho, said during the R&D center's inauguration. "The U.S. R&D center will contribute to building infrastructure for a localized manufacturing line as well as strengthening development for localized products."
In a separate press release, the CEO of KGC US, Heung Sil Lee, further said, "This will be a momentous year for our global business. As we meet the unique needs of our U.S. customers by actively developing products specifically tailored to their lifestyles."
